Evaluation of PAX3 genetic variants and nevus number

Pigment Cell and Melanoma Research

Volumn 26, Issue 5, 2013, Pages 666-676

  Ogbah, Zighereda ^a   Badenas, Celia ^a,b   Harland, Mark ^c   Puig Butille, Joan A ^a,b   Elliot, Fay ^c   Bonifaci, Nuria ^d   Guino, Elisabet ^d   Randerson Moor, Julie ^c   Chan, May ^c   Iles, Mark M ^c   Glass, Daniel ^e,f   Brown, Andrew A ^e   Carrera, Cristina ^a,b   Kolm, Isabel ^a   Bataille, Veronique ^e   Spector, Timothy D ^e   Malvehy, Josep ^a,b   Newton Bishop, Julia ^c   Pujana, Miquel A ^d   Bishop, Tim ^c   Puig, Susana ^a,b   more..

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f EALING HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Melanoma; Nevus; PAX3; SNP; Susceptibility

Indexed keywords

TRANSCRIPTION FACTOR PAX3;

ARTICLE; CONTROLLED STUDY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MELANOMA; NEVUS; PHENOTYPE; PROTEIN BINDING; SINGLE NUCLEOTIDE POLYMORPHISM;

MELANOMA; NEVUS; PAX3; SNP; SUSCEPTIBILITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; NEVUS; PAIRED BOX TRANSCRIPTION FACTORS; POLYMORPHISM, SINGLE NUCLEOTIDE; SKIN NEOPLASMS; SPAIN; YOUNG ADULT;

EID: 84883034983     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12130     Document Type: Article

References (48)

1. Aguilera, P., Puig, S., Guilabert, A., Julià, M., Romero, D., Vicente, A., González-Enseñat, M.A., and Malvehy, J. (2009). Prevalence study of nevi in children from Barcelona. Dermatology 218, 203-214.
2. Andrew, T., Hart, D.J., Snieder, H., De Lange, M., Spector, T.D., and MacGregor, A.J. (2001). Are twins and singletons comparable? A study of disease-related and lifestyle characteristics in adult women. Twin Res. 4, 464-477.
3. Bahuau, M., Vidaud, D., Kujas, M. et al. (1997). Familial aggregation of malignant melanoma/dysplastic naevi and tumours of the nervous system: an original syndrome of tumour proneness. Ann. Genet. 40, 78-91.
4. Bataille, V., Bishop, J.A., Sasieni, P., Swerdlow, A.J., Pinney, E., Griffiths, K., and Cuzick, J. (1996). Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br. J. Cancer 73, 1605-1611.
5. Bataille, V., Snieder, H., MacGregor, A.J., Sasieni, P., and Spector, T.D. (2000). Genetics of risk factors for melanoma: an adult twin study of nevi and freckles. J. Natl Cancer Inst. 92, 457-463.
6. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., and Golani, I. (2001). Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 125, 279-284.
7. Bishop, J.A., Wachsmuth, R.C., Harland, M., Bataille, V., Pinney, E., MacK, P., Baglietto, L., Cuzick, J., and Bishop, D.T. (2000). Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J. Invest. Dermatol. 114, 28-33.
8. Blake, J.A., and Ziman, M.R. (2005). Pax3 transcripts in melanoblast development. Dev. Growth Differ. 47, 627-635.
9. Bonvin, E., Falletta, P., Shaw, H., Delmas, V., and Goding, C.R. (2012). A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma. Mol. Cell. Biol. 32, 4674-4683.
10. Briollais, L., Chompret, A., Guilloud-Bataille, M., Bressac-De Paillerets, B., Avril, M.F., and Demenais, F. (2000). Patterns of familial aggregation of three melanoma risk factors: great number of naevi, light phototype and high degree of sun exposure. Int. J. Epidemiol. 29, 408-415.
11. Chalepakis, G., Jones, F.S., Edelman, G.M., and Gruss, P. (1994). Pax-3 contains domains for transcription activation and transcription inhibition. Proc. Natl Acad. Sci. USA 91, 12745-12749.
12. Chang, Y.M., Newton-Bishop, J.A., Bishop, D.T. et al. (2009). A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int. J. Cancer 124, 420-428.
13. Conde, L., Vaquerizas, J.M., Santoyo, J., Al-Shahrour, F., Ruiz-Llorente, S., Robledo, M., and Dopazo, J. (2004). PupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level. Nucleic Acids Res 32, W242-248.
14. Corry, G.N., and Underhill, D.A. (2005). Pax3 target gene recognition occurs through distinct modes that are differentially affected by disease-associated mutations. Pigment Cell Res. 18, 427-438.
15. de Bakker, P.I., Yelensky, R., Pe'er, I., Gabriel, S.B., Daly, M.J., and Altshuler, D. (2005). Efficiency and power in genetic association studies. Nat Genet 37, 1217-1223.
16. Duffy, D.L., Iles, M.M., Glass, D. et al. (2010). IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am. J. Hum. Genet. 87, 6-16.
17. Easton, D.F., Cox, G.M., MacDonald, A.M., and Ponder, B.A. (1991). Genetic susceptibility to naevi-a twin study. Br. J. Cancer 64, 1164-1167.
18. Falchi, M., Spector, T.D., Perks, U., Kato, B.S., and Bataille, V. (2006). Genome-wide search for nevus density shows linkage to two melanoma loci on chromosome 9 and identifies a new QTL on 5q31 in an adult twin cohort. Hum. Mol. Genet. 15, 2975-2979.
19. Falchi, M., Bataille, V., Hayward, N.K. et al. (2009). Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat. Genet. 41, 915-919.
20. Fernandez, L.P., Milne, R.L., Pita, G. et al. (2009). Pigmentation-related genes and their implication in malignant melanoma susceptibility. Exp. Dermatol. 18, 634-642.
21. Florell, S.R., Meyer, L.J., Boucher, K.M. et al. (2004). Longitudinal assessment of the nevus phenotype in a melanoma kindred. J. Invest. Dermatol. 123, 576-582.
22. Gandini, S., Sera, F., Cattaruzza, M.S., Pasquini, P., Abeni, D., Boyle, P., and Melchi, C.F. (2005). Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur. J. Cancer 41, 28-44.
23. Gonzalez, J.R., Armengol, L., Sole, X., Guino, E., Mercader, J.M., Estivil, l.X., and Moreno, V. (2007). SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23, 644-645.
24. He, S., Yoon, H.S., Suh, B.J., and Eccles, M.R. (2010). PAX3 Is extensively expressed in benign and malignant tissues of the melanocytic lineage in humans. J. Invest. Dermatol. 130, 1465-1468.
25. Koyanagi, K., Kuo, C., Nakagawa, T., Mori, T., Ueno, H., Lorico, A.R. Jr., Wang, H.J., Hseuh, E., O'day, S.J., and Hoon, D.S. (2005). Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin. Chem. 51, 981-988.
26. Kubic, J.D., Young, K.P., Plummer, R.S., Ludvik, A.E., and Lang, D. (2008). Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell Melanoma Res. 21, 627-645.
27. Lang, D., Lu, M.M., Huang, L., Engleka, K.A., Zhang, M., Chu, E.Y., Lipner, S., Skoultchi, A., Millar, S.E., and Epstein, J.A. (2005). Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433, 884-887.
28. Leiter, U., and Garbe, C. (2008). Epidemiology of melanoma and nonmelanoma skin cancer-the role of sunlight. Adv. Exp. Med. Biol. 624, 89-103.
29. Medic, S., and Ziman, M. (2009). PAX3 across the spectrum: from melanoblast to melanoma. Crit. Rev. Biochem. Mol. Biol. 44, 85-97.
30. Medic, S., and Ziman, M. (2010). PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas). PLoS ONE 5, e9977.
31. Medic, S., Rizos, H., and Ziman, M. (2011). Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochem. Biophys. Res. Commun. 411, 832-837.
32. Nan, H., Xu, M., Zhang, J. et al. (2011). Genome-wide association study identifies nidogen 1 (NID1) as a susceptibility locus to cutaneous nevi and melanoma risk. Hum. Mol. Genet. 20, 2673-2679.
33. Nica, A.C., Parts, L., Glass, D. et al. (2011). The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet. 7, e1002003.
34. Plummer, R.S., Shea, C.R., Nelson, M., Powell, S.K., Freeman, D.M., Dan, C.P., and Lang, D. (2008). PAX3 expression in primary melanomas and nevi. Mod. Pathol. 21, 525-530.
35. Pritchard, C., Grosveld, G., and Hollenbach, A.D. (2003). Alternative splicing of Pax3 produces a transcriptionally inactive protein. Gene 305, 61-69.
36. Puig, S., Ruiz, A., Castel, T., Volpini, V., Malvehy, J., Cardellach, F., Lynch, M., Mascaro, J.M., and Estivill, X. (1997). Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene. Hum. Genet. 101, 359-364.
37. Randerson-Moor, J.A., Taylor, J.C., Elliott, F. et al. (2009). Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur. J. Cancer 45, 3271-3281.
38. Richards, J.B., Rivadeneira, F., Inouye, M. et al. (2008). Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371, 1505-1512.
39. Sauna, Z.E., and Kimchi-Sarfaty, C. (2011). Understanding the contribution of synonymous mutations to human disease. Nat. Rev. Genet. 12, 683-691.
40. Scholl, F.A., Kamarashev, J., Murmann, O.V., Geertsen, R., Dummer, R., and Schafer, B.W. (2001). PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res. 61, 823-826.
41. Takeuchi, H., Morton, D.L., Kuo, C., Turner, R.R., Elashoff, D., Elashoff, R., Taback, B., Fujimoto, A., and Hoon, D.S. (2004). Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J. Clin. Oncol. 22, 2671-2680.
42. Wachsmuth, R.C., Gaut, R.M., Barrett, J.H., Saunders, C.L., Randerson-Moor, J.A., Eldridge, A., Martin, N.G., Bishop, T.D., and Newton Bishop, J.A. (2001). Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J. Invest. Dermatol. 117, 348-352.
43. Wachsmuth, R.C., Turner, F., Barrett, J.H., Gaut, R., Randerson-Moor, J.A., Bishop, D.T., and Bishop, J.A. (2005). The effect of sun exposure in determining nevus density in UK adolescent twins. J. Invest. Dermatol. 124, 56-62.
44. Yang, G., Li, Y., Nishimura, E.K., Xin, H., Zhou, A., Guo, Y., Dong, L., Denning, M.F., Nickoloff, B.J., and Cui, R. (2008). Inhibition of PAX3 by TGF-beta modulates melanocyte viability. Mol. Cell 32, 554-563.
45. Yang, T.P., Beazley, C., Montgomery, S.B., Dimas, A.S., Gutierrez-Arcelus, M., Stranger, B.E., Deloukas, P., and Dermitzakis, E.T. (2010). Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 26, 2474-2476.
46. Yokoyama, S., Woods, S.L., Boyle, G.M. et al. (2011). A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480, 99-103.
47. Zhu, G., Duffy, D.L., Eldridge, A. et al. (1999). A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am. J. Hum. Genet. 65, 483-492.
48. Zhu, G., Montgomery, G.W., James, M.R., Trent, J.M., Hayward, N.K., Martin, N.G., and Duffy, D.L. (2007). A genome-wide scan for naevus count: linkage to CDKN2A and to other chromosome regions. Eur. J. Hum. Genet. 15, 94-102.